Company intelligence / Profile preview

LVIS

Palo Alto, California, United Stateslicense.doe.in.gov ↗

Ownership: Private
Employees: ~35
Development stage: Other

Overview

LVIS has developed NeuroMatch®, an AI-powered cloud-based EEG analysis platform that enables rapid, automated interpretation of neurological data. The product has received FDA clearance in the US and MFDS clearance in South Korea. It is deployed at major hospitals for epilepsy diagnosis, with ongoing expansion into broader neurological disease diagnostics.

Therapeutic areas: Neurology
Modalities: DeviceSoftware as a Medical Device (SaMD)Data analysis platform
Industry: Physiological Monitoring

Beyond the preview

Go deeper on LVIS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LVIS.

Explore the full profile